StageIII colon cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Histological confirmation of colorectal cancer with curative resection (2) Patients Who scheduled to receive capecitabine together with oxaliplatin (CapeOx) treatment. (3) Written informed consent. (4) 20 years old or more when received informed consent. (5) Eastern Cooperative Oncology Group (ECOG) performance status (PS) : 0 - 1. (6) Patients who received no previous chemotherapy or radiotherapy treatment. (7)Patients with oral intake is possible
Exclusion criteria
Exclusion criteria: (1)Patient condition corresponds with section of contraindication or contraindication in combination for the administration of Capecitabine and Oxaliplatin. (2)Not appropriate for the study at the physician's assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hand-Foot Syndrome (> grade 3) events rate. | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion rate. Evaluation of QOL(Skin Toxicity - Related symptoms) 3-year Relapse-free survival. Compliance. Relative dose intensity. Duration of a call. Patient satisfaction for phone support Program. Number of all outpatient visits. Number of phone times for Unscheduled. Number of phone times after the Fourth course. | — |
Countries
Japan
Contacts
Toho University Omori Medical Center Division of Gastroenterological Surgery